The insomnia market is expected to increase throughout the study period due to several factors. Increased awareness of the disease has led to more cases being treated, contributing to market growth. Additionally, the rising number of clinical trials of therapies including Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others is a significant driver of the market's expansion.
LAS VEGAS, June 18, 2026 /PRNewswire/ -- Recently published Insomnia Market Insights report includes a comprehensive understanding of current treatment practices, insomnia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Insomnia Market Summary
- The total insomnia treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest insomnia treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- In 2025, diagnosed prevalent cases of insomnia across the 7MM were estimated at approximately 90 million.
- Leading insomnia companies, such as Johnson & Johnson, Vanda Pharmaceuticals, Idorsia, EUSOL Biotech, and others, are developing new insomnia treatment drugs that can be available in the insomnia market in the coming years.
- The promising insomnia therapies in clinical trials include Seltorexant (JNJ-42847922), HETLIOZ (tasimelteon), Daridorexant, SM-1, and others.
Discover which insomnia drug class will dominate the market @ https://www.delveinsight.com/report-store/insomnia-market
Key Factors Driving the Growth of the Insomnia Market
- Rising Prevalence of Sleep Disorders: Increasing cases of chronic insomnia, stress-related sleep disturbances, and irregular sleep patterns are significantly expanding the patient pool globally.
- Breakthrough Developments in Insomnia Therapeutics: Significant developments in the treatment regime have led to the approval of novel class therapies such as orexin antagonists and melatonin agonists, along with CBTs, that address insomnia with associated conditions.
- Launch of Emerging Drugs: The dynamics of the insomnia market are expected to change in the coming years, owing to the launch of emerging therapies such as Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others.
Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that the insomnia market is entering a transformative phase, driven by rising awareness of sleep health, increasing stress-related disorders, and the growing demand for safer, non-habit-forming therapies. Novel orexin receptor antagonists and digital therapeutics are reshaping the competitive landscape.
Insomnia Market Analysis
- The primary objective of insomnia treatment is to enhance a patient's ability to fall asleep, remain asleep, wake up refreshed, and function effectively during the day. Current clinical guidelines emphasize behavioral and psychological interventions, particularly Cognitive Behavioral Therapy for Insomnia (CBT-I), as the first-line treatment approach.
- Pharmacological options approved by the FDA for insomnia management include several drug classes. These comprise the newer orexin receptor antagonists, benzodiazepines, non-benzodiazepine agents, as well as melatonin receptor agonists.
- Products available across these therapeutic categories include AMBIEN, SONATA, HALCION, RESTORIL, ZOLPIMIST, SILENOR, ROZEREM, DAYVIGO, QUVIVIQ, BELSOMRA, CIRCADIN, and VORZZZ, among others.
- Most of these therapies have been marketed for more than a decade and are now available in generic forms. However, orexin receptor antagonists remain a relatively novel class, represented by products such as Merck's BELSOMRA, Eisai's DAYVIGO, QUVIVIQ (daridorexant), and the recently introduced VORZZZ.
- Although the current insomnia pipeline is relatively limited, several companies continue to explore new therapeutic candidates. Key pipeline therapies under investigation include Johnson & Johnson's seltorexant and Vanda Pharmaceuticals' HETLIOZ, alongside other emerging treatment options.
Insomnia Competitive Landscape
Some of the insomnia drugs under development include Seltorexant (JNJ-42847922) (Johnson & Johnson), HETLIOZ (tasimelteon) (Vanda Pharmaceuticals), Daridorexant (Idorsia), SM-1 (EUSOL Biotech), and others.
Janssen Pharmaceutical's seltorexant (JNJ-42847922) is a selective orexin-2 receptor antagonist being investigated as an adjunctive treatment for major depressive disorder (MDD) as well as for insomnia disorder.
Vanda Pharmaceuticals' HETLIOZ (tasimelteon), also referred to as VEC-162, is a melatonin receptor agonist that targets the human MT1 and MT2 receptors, showing higher affinity for MT2. Acting as a circadian rhythm regulator, the therapy helps reset the body's internal clock through its action on the suprachiasmatic nucleus (SCN) in the hypothalamus.
The anticipated launch of these emerging therapies are poised to transform the insomnia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the insomnia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which companies are leading the insomnia pipeline @ Insomnia Drugs
Recent Developments in the Insomnia Market
- In September 2025, Johnson & Johnson reported results from the Phase III MDD3005 26-week clinical trial evaluating Seltorexant as an adjunctive treatment in adults and elderly patients with MDD experiencing insomnia symptoms. The study assessed the efficacy and safety of seltorexant compared with Quetiapine Extended-Release in patients with MDD and comorbid sleep disturbances.
- In September 2025, Vanda Pharmaceuticals reported the publication of a study evaluating tasimelteon (marketed as HETLIOZ) in PLOS One, assessing its efficacy in patients with Primary Insomnia. The multicenter, randomized, double-blind, placebo-controlled trial demonstrated that tasimelteon met its primary endpoint, showing a mean improvement in latency to persistent sleep (LPS) from baseline to the average of Nights 1 and 8. Vanda Pharmaceuticals continues to pursue the development of tasimelteon for insomnia following the 2024 refusal decision by the US FDA.
- In August 2025, the Pharmaceuticals and Medical Devices Agency (PMDA) approved VORZZZ (vornorexant), developed by Taisho Pharmaceutical, for the treatment of Insomnia in Japan. Vornorexant is a novel dual orexin receptor antagonist (DORA) designed with a short half-life to improve sleep onset and sleep maintenance while minimizing next-day residual drowsiness, offering a new orexin-targeting therapeutic option for patients experiencing difficulty initiating or maintaining sleep.
What is Insomnia?
Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early and being unable to return to sleep. It can be short-term, often triggered by stress, lifestyle changes, or illness, or chronic, lasting for months or longer. People with insomnia frequently experience daytime fatigue, poor concentration, mood disturbances, and reduced productivity, which can significantly affect overall quality of life. The condition may be associated with mental health disorders, neurological conditions, chronic pain, or certain medications, making it an important public health concern worldwide.
Insomnia Epidemiology Segmentation
The insomnia epidemiology section provides insights into the historical and current insomnia patient pool and forecasted trends for the leading markets. According to DelveInsight, the total diagnosed prevalent cases of insomnia in the US comprised approximately 60 million in 2025 and are projected to increase during the forecast period.
The insomnia treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Total Diagnosed Prevalent Cases of Insomnia
- Type-specific Diagnosed Prevalent Cases of Insomnia
- Gender-specific Diagnosed Prevalent Cases of Insomnia
- Age-specific Diagnosed Prevalent Cases of Insomnia
Insomnia Market Report Metrics | Details |
Study Period | 2022-2036 |
Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Insomnia Epidemiology Segmentation | Total Diagnosed Prevalent Cases of Insomnia, Type-specific Diagnosed Prevalent Cases of Insomnia, Gender-specific Diagnosed Prevalent Cases of Insomnia, and Age-specific Diagnosed Prevalent Cases of Insomnia |
Key Insomnia Companies | Johnson & Johnson, Vanda Pharmaceuticals, Idorsia, EUSOL Biotech, Cosette Pharmaceuticals, Sanofi, Pfizer, Mallinckrodt Pharmaceuticals, Arovella Therapeutics, Currax Pharmaceuticals, Takeda, Eisai, Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Neurim Pharmaceuticals, Taisho Pharmaceutical, and others |
Key Insomnia Therapies | Seltorexant (JNJ-42847922), HETLIOZ (tasimelteon), Daridorexant, SM-1, AMBIEN, SONATA, HALCION, RESTORIL, ZOLPIMIST, SILENOR, ROZEREM, DAYVIGO, QUVIVIQ, BELSOMRA, CIRCADIN, VORZZZ, and others |
Scope of the Insomnia Market Report
- Insomnia Patient Population Forecast
- Insomnia Therapeutics Market Size
- Insomnia Pipeline Analysis
- Insomnia Market Size and Trends
- Insomnia Market Opportunity
- Insomnia Market Unmet Needs
- KOL's Views on Insomnia
- Insomnia Market Access and Reimbursement
Download the report to understand how fast is the insomnia therapeutics market growing @ Insomnia Market Analysis
Table of Contents
1 | Insomnia Market Key Insights |
2 | Insomnia Market Report Introduction |
3 | Insomnia Market Overview at a Glance |
3.1 | Market Share (%) Distribution of Insomnia by Therapies in the 7MM in 2025 |
3.2 | Market Share (%) Distribution of Insomnia by Therapies in the 7MM in 2036 |
4 | Methodology |
5 | Executive Summary |
6 | Key Events |
7 | Disease Background and Overview |
7.1 | Introduction |
7.2 | Signs and symptoms |
7.3 | Causes |
7.4 | Risk Factors |
7.5 | Classification |
7.6 | Diagnostic Approach for Insomnia |
7.7 | Treatment for Insomnia |
8 | Epidemiology and Patient Population |
8.1 | Key Findings |
8.2 | Assumptions and Rationale: 7MM |
8.3 | Total Diagnosed Prevalent Cases of Insomnia in the 7MM |
8.4 | The United States |
8.4.1 | Total Diagnosed Prevalent Cases of Insomnia in the US |
8.4.2 | Type-specific Diagnosed Prevalent Cases of Insomnia in the US |
8.4.3 | Gender-specific Diagnosed Prevalent Cases of Insomnia in the US |
8.4.4 | Age-specific Diagnosed Prevalent Cases of Insomnia in the US |
8.5 | EU4 and the UK |
8.6 | Japan |
9 | Patient Journey |
10 | Marketed Insomnia Drugs |
10.1 | Key Cross Competition |
10.2 | DAYVIGO (lemborexant): Eisai |
10.2.1 | Product Description |
10.2.2 | Regulatory Milestones |
10.2.3 | Other Developmental Activities |
10.2.4 | Clinical Development |
10.2.5 | Safety and Efficacy |
10.2.6 | Analyst Views |
10.3 | QUVIVIQ (daridorexant): Idorsia Pharmaceutical/Mochida Pharmaceutical |
List to be continued in the report… | |
11 | Emerging Insomnia Drugs |
11.1 | Key Cross Competition |
11.2 | Seltorexant (JNJ-42847922): Johnson & Johnson |
11.2.1 | Product description |
11.2.2 | Other development activities |
11.2.3 | Clinical trials information |
11.2.4 | Safety and efficacy |
11.2.5 | Analyst Views |
11.3 | HETLIOZ (tasimelteon): Vanda Pharmaceuticals |
List to be continued in the report… | |
12 | Insomnia: Market Analysis |
12.1 | Key Findings |
12.2 | Key Insomnia Market Forecast Assumptions |
12.3 | Insomnia Market Outlook |
12.4 | Attribute Analysis |
12.5 | Total Market Size of Insomnia in the 7MM |
12.6 | Total Market Size of Insomnia by Therapies in the 7MM |
12.7 | Market Size of Insomnia in the US |
12.7.1 | Total Market Size of Insomnia |
12.7.2 | The Market Size of Insomnia by Therapies |
12.8 | Market Size of Insomnia in EU4 and the UK |
12.9 | Market Size of Insomnia in Japan |
13 | Key Opinion Leaders' Views |
14 | Unmet Needs |
15 | SWOT Analysis |
16 | Market Access and Reimbursement |
16.1 | The US |
16.2 | In EU4 and the UK |
16.3 | Japan |
17 | Bibliography |
18 | Acronyms and Abbreviations |
19 | Insomnia Market Report Methodology |
Related Reports
Insomnia Clinical Trial Analysis
Insomnia Pipeline Insight - 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key insomnia companies, including Johnson & Johnson, Vanda Pharmaceuticals, Idorsia, EUSOL Biotech, Cosette Pharmaceuticals, Sanofi, Pfizer, Mallinckrodt Pharmaceuticals, Arovella Therapeutics, Currax Pharmaceuticals, Takeda, Eisai, Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Neurim Pharmaceuticals, Taisho Pharmaceutical, and others.
Chronic Insomnia Market
Chronic Insomnia Market Insights, Epidemiology, and Market Forecast - 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic insomnia companies, including Eisai Inc., Merck & Co., Idorsia Pharmaceuticals, Janssen Research & Development, Minerva Neurosciences, Sequential Medicine Ltd., and others.
Obstructive Sleep Apnea Market
Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obstructive sleep apnea companies, including Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.
Narcolepsy Market
Narcolepsy Market Insights, Epidemiology, and Market Forecast - 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key narcolepsy companies, including Jazz Pharmaceuticals, Harmony Biosciences, Takeda, Centessa Pharmaceuticals, Alkermes, Axsome Therapeutics, Avadel Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/insomnia-market-witnesses-robust-growth-during-the-forecast-period-20262036-with-emerging-orexin-receptor-antagonists-and-melatonin-receptor-agonist--delveinsight-302804001.html
